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ABSTRACT 
Bluetongue virus (BTV) is an economically important member of the genus 
Orbivirus and closely related to African horse sickness virus (AHSV) and Epizootic 
hemorrhagic disease virus (EHDV). Currently, 26 different serotypes of BTV are 
known. The virus is transmitted by blood-feeding Culicoides midges and causes 
disease (bluetongue [BT]) in ruminants. In 2006/2007, BTV serotype 8 (BTV-8) 
caused  widespread outbreaks of BT amongst livestock in Europe, which were 
eventually controlled employing a conventionally inactivated BTV vaccine. 
However, this vaccine did not allow the discrimination of infected from vaccinated 
animals (DIVA) by the commonly used VP7 cELISA. 
RNA replicon vectors based on propagation-incompetent recombinant vesicular 
stomatitis virus (VSV) represent a novel vaccine platform that combines the 
efficacy of live attenuated vaccines with the safety of inactivated vaccines. Our 
goal was to generate an RNA replicon vaccine for BTV-8, which is safe, 
efficacious, adaptable to emerging orbivirus infections , and compliant with the 
DIVA principle.  
The VP2, VP5, VP3 and VP7 genes encoding the BTV-8 capsid proteins, as well 
as the non-structural proteins NS1 and NS3 were inserted into a VSV vector 
genome lacking the essential VSV glycoprotein (G) gene. Infectious virus replicon 
particles (VRP) were produced on a transgenic helper cell line providing the VSV G 
protein in trans. Expression of antigens in vitro was analysed by 
immunofluorescence using monoclonal and polyclonal antibodies.  
In a pilot study, sheep were immunized with two different VRP-based vaccine 
candidates, one comprising the BTV-8 antigens VP2, VP5, VP3, VP7, NS1, and 
NS3, the other one containing antigens VP3, VP7, NS1, and NS3. Control animals 
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received VRPs containing an irrelevant antigen. Virus neutralizing antibodies and 
protection after BTV-8 challenge were evaluated  and compared to animals 
immunized with the conventionally inactivated vaccine. Full protection was induced 
only when the two antigens VP2 and VP5 were included in the vaccine.  
To further evaluate if VP2 alone, a combination of VP2 and VP5 or VP5 alone were 
necessary for complete protection, we performed a second animal trial. 
Interestingly, VP2 as well as the combination of VP2 and VP5 but not VP5 alone 
conferred full protection in terms of neutralizing antibodies, and protection from 
clinical signs and viremia after BTV-8 challenge.  
These results show that the VSV replicon system represents a safe, efficacious 
and DIVA-compliant vaccine against BTV as well as a possible platform for 
protection against other Orbiviruses, such as AHSV and EHDV. 
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ABBREVIATIONS 
BTV  Bluetongue virus 
VSV  Vesicular stomatitis virus 
VRP  Virus replicon particles 
GFP or * Green fluorescent protein 
IFT  Immunofluorscent test/assay 
MOI  Multiplicity of infection 
NS  Non-structural protein 
VP  Viral protein 
G  Glycoprotein 
∆G  lacking Glycoprotein 
AHSV  African horse sickness virus 
EHDV  Epizootic hemorrhagic disease virus 
RNA  Ribonucleic acid 
kDA  kiloDalton 
ELISA  Enzyme linked immunosorbent assay 
dsRNA double-stranded ribonucleic acid 
kb  kilobases 
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INTRODUCTION BLUETONGUE 
Bluetongue virus (BTV) is an Orbivirus of the Reoviridae family, and the causative 
agent of a haemorrhagic disease (bluetongue [BT]) in ruminants, mainly sheep [1]. 
There are currently  26 recognised serotypes of BTV, which are transmitted by blood-
feeding Culicoides midges and sometimes  vertically in animals [2, 3]. BTV is closely 
related to African horse sickness virus (AHSV). 
 
History and Epidemiology 
Bluetongue was first described in Merino sheep in the late 19th century in South 
Africa and got its name due to severe cyanosis of the tongue of some severely 
affected sheep [4]. Later in the 1990s, it was determined that BT was a  disease of  
ruminants occurring worldwide from latitudes of approximately 40 degrees North to 
35 degrees South [5]. Furthermore, the disease was responsible for considerable 
economic losses especially at the incursional margins of the global range of BTV 
infection [6]  (Figure 1). Although BTV had transiently made brief  incursions into 
Southern Europe, these did not persist  in the continent [5]. However, between 1998 
and 2001, eight BTV strains of five different serotypes (BTV-1, 2, 4, 8, 9 and 16) 
emerged in several countries around the northern rim of the Mediterranean Basin 
where they had previously not been recorded, likely because of climatic changes 
which allowed overwintering of the virus in  Culicoides vector midges [7]. 
A novel strain of BTV serotype 8 (BTV-8), which had never previously been detected 
in Europe, emerged in 2006 as an epidemic wave in Western and Northern Europe 
[4, 8, 9]. This outbreak had a significant economic impact, not only because of 
morbidity and mortality caused by the disease in sheep and cattle, but also because 
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of restrictions imposed on livestock movement and trade [10]. In August 2006, BTV-8 
was detected in sheep in the Netherlands, followed by Germany, Belgium and 
France. In 2007, the outbreak was confirmed in Switzerland, the United Kingdom, 
Luxembourg, Denmark and the Czech Republic. In 2008, Spain, Italy, Greece and 
Austria also detected BTV-8 infection in cattle and sheep. It remains uncertain 
precisely  how BTV-8  arrived in Northern Europe, but the absence of outbreaks in 
southern parts of the continent points towards a direct entry mechanism rather than a 
linear extension from its ancestor, potentially a Western lineage virus from sub-
Saharan Africa [11]. 
 
Figure 1. Map showing distribution limits of BTV and Culicoides midges prior to 1998, reviewed 
by Purse et al. [12]. The distribution limits of BTV are demarcated by red lines and are located 
broadly between the latitudes 35°S and 40°N (indicated by dashed lines). Countries with occurrence of 
Culicoides immicola midges are highlighted by dark green colour. Other important Culicoides vectors 
are listed next to the continent in which they are involved in transmission. 
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Figure 2. Distribution of BTV-8 during the outbreak in northern Europe between 2006 and 2007, 
reviewed by Saegerman et al. [13]. Monthly distribution of confirmed bluetongue virus 8 (BTV-8) 
outbreaks in northern and central Europe from August 17, 2006, through February 1, 2007. After 
January 1, 2007, few BTV cases were reported; those that were probably involved animals that had 
been infected, but not detected, in 2006. 
 
Bluetongue disease 
BTV is transmitted to livestock by blood-feeding Culicoides midges, in Europe mainly 
by C. imicola, C. pulicaris and C. obsoletus. In cattle, goats, and wild ruminants, BTV 
infection is typically asymptomatic despite prolonged viremia. These host species 
represent a potential reservoir for unnoticed dissemination of BTV in ruminant 
populations. In sheep, however, BTV infection often results in an acute disease with 
associated high morbidity and mortality, depending on the virulence of the virus and 
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the sheep breed affected [14]. Following an initial replication in the lymph nodes, BTV 
targets endothelium and mononuclear phagocytes [15]. After an incubation period of 
2 to 15 days, clinical signs in the acute phase of disease comprise high fever, 
salivation, depression, nasal discharge, hyperaemia and congestion of the muzzle, 
lips, face, eyelids and ears leading to tissue oedema (Figure 3 A). Ulcerations and 
necrosis of the mucosae of the mouth are often observed, the tongue may become 
hyperaemic and oedematous. Lameness due to coronitis, pneumonia or lung 
oedema can be observed in severe cases. In cases with fatal outcome, sheep 
usually die after 8 to 10 days. 
Certain strains of BTV, notably the northern European strain of BTV-8, can cross the 
placental barrier, leading to infection of the developing fetus [3]. Hence, abortions 
and malformations of offspring are frequently associated with infection of pregnant 
animals with certain strains of the virus [16-18].  
Frequently observed pathological findings comprise hemorrhages at the base of the 
pulmonary artery (A. pulmonalis), the papillary muscles of the left ventricle of the 
heart , enlarged haemorrhagic lymph nodes, erosions on ruminal pillars, and  ulcers 
of the mucosal lining throughout the upper gastrointestinal tract (Figure 3 B-F). 
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Figure 3. Acute disease and pathological findings in Bluetongue virus-infected sheep. 
Bluetongue disease gross lesions in BTV-8 infected sheep at 8 dpi; the animal displays severe facial 
oedema, nasal discharge and salivation (A). Pathological findings at 14 dpi (B) hard palate with linear 
hemorrhages following the tips of the rugae, (C) haemorrhagic focus at the base of the pulmonary 
artery, (D) several hemorrhagic foci covered with fibrionecrotic material at the pilae ruminis, (E) 
hemorrhages at the papillary muscle of the heart, (F) petechiae of the coronary band. 
 
Structure and replication cycle 
The BTV genome consists of 10 segments of dsRNA, which encode 7 structural 
(VP1 - VP7) and 5 non-structural proteins (NS1 – NS4, NS3a) [19, 20]. The non-
enveloped icosahedral virion is composed of three concentric protein layers that 
surround the inner core (Figure 4). The core includes the viral RNA, VP1 (RNA 
polymerase), VP4 (capping enzyme), and VP6 (helicase) [21, 22]. The inner capsid 
layer consists of a heterodimer of VP3 that forms a scaffold for VP7. The outer 
capsid is formed by the viral proteins VP2 and VP5, which are responsible for 
receptor binding in the mammalian host, hemagglutination, and membrane 
penetration, respectively [23, 24] (Figure 5). The large (110 kDa) attachment protein 
VP2 induces virus-neutralizing antibodies [25]. However, VP2 is highly variable and 
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currently 26 different BTV serotypes can be distinguished by antibodies that show 
little or no cross-neutralizing activity [4]. Binding of VP5 to VP2 leads to a VP2 
conformational change, which may affect the epitopes of neutralizing antibodies [26, 
27]. VP5, which is significantly more conserved than VP2, has been shown to be a 
membrane penetration protein and facilitates the release of the core from the 
endosome into the cytoplasma [28]. All other structural and non-structural proteins 
are relatively conserved among different BTV serotypes. As a consequence, most 
ELISAs for detection of group-specific -BTV antibodies employ the VP7 antigen [29]. 
 
 
 
Figure 4. Schematic structure of BTV, image taken from Schwartz-Cornil et al  [4]. The outer 
capsid of BTV is formed by the viral proteins VP2 and VP5, which surround the intermediate layer built 
by VP7. VP3 forms the inner (core) capsid of the virus, which contains 10 segments of its dsRNA 
genome. 
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Figure 5. Overview of the replication cycle, adapted from Patel and Roy [30]. Following VP2-
mediated attachment to sialic acid-containing receptors, clathrin- mediated endocytosis takes place. 
Acidification of the endosome followed by VP5-mediated membrane permeabilisation leads to release 
of the core particle into the cytosol of the host cell. After transcription and translation of the viral 
proteins, core particles are assembled in viral inclusion bodies and virions are assembled. They then 
egresses via budding or host cell lysis. 
 
Vaccine strategies 
Currently available commercial vaccines against BTV are either attenuated or 
inactivated. Live-attenuated (MLV) vaccines have been used to control BT in sheep 
in Southern Africa, the United States and Israel as  they induce solid immunity and 
can  be produced relatively cheaply [31]. However, potential complications of MLV 
vaccines include transient viremia after vaccination – possibly leading to further 
distribution by vector midges - making them unsuitable candidates for use in non-
endemic regions [32, 33]. The epizootic of BTV-8 which struck Europe between 2006 
and 2008 was controlled by an extensive vaccination campaign using whole 
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inactivated BTV-8. Although these vaccines induced strong protection against BTV-8 
infection and disease, they did not allow simple serological discrimination of infected 
from vaccinated animals (DIVA). Furthermore, vaccine production required the 
production of large amounts of infectious virus in cell culture, proper virus 
inactivation, and formulation of the antigen with adjuvant, all of which delayed 
production and added to the cost of producing the vaccine. Importantly, inactivated 
virus vaccines may not be suitable for the control of all serotypes of BTV as, for 
example, serotype 25 cannot yet be propagated in cell culture [34]. 
Much effort has been devoted to the development of alternative vaccine candidates, 
to overcome the drawbacks of conventional vaccines. Virus-like particles were 
produced using recombinant baculovirus-encoded BTV  proteins that were expressed 
using baculovirus expression vectors [35, 36]. They proved to be promising 
candidates for the production of  multi-serotype vaccines, but also caused concerns 
regarding potential replication in insect vectors in the field  [37]. Other recombinant 
viruses encoding different BTV-antigens such as vaccinia viruses [38], canarypox 
viruses [39], capripox viruses [40] and herpes viruses [41] have also been proposed. 
These studies already revealed the importance of the two components  of the outer 
BTV shell, VP2 and VP5, for protection [42] 
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INTRODUCTION TO VSV REPLICONS 
Vesicular stomatitis virus (VSV) structure and replication 
VSV is a non-segmented negative-strand RNA virus of the family Rhabdoviridae, and 
is known to trigger a robust humoral immune response in many different host species 
[43]. Virions are bullet-shaped particles with genomes which encode for the five viral 
proteins, namely nucleoprotein (N), phosphoprotein (P), matrix protein (M), 
glycoprotein (G) and the large RNA polymerase (L), resulting in a total size of 
approximately 11.2 kb. (Figure 6). The virus is characterized by a broad cell tropism 
with propagation to high titres and cytopathogenicity (Figure 7).  
 
 
Figure 6. Schematic overview of VSV, adapted from The Swiss Institute of Bioinformatics 
(http://viralzone.expasy.org). VSV virions are bullet-shaped particles with genomes encodes for the 
five viral proteins nucleoprotein (N), phosphoprotein (P), matrix protein (M), glycoprotein (G) and the 
large RNA polymerase (L). The transmembrane G protein is embedded in the viral envelope and is 
essential for receptor binding and fusion. A ribonucleocapsid complex (RNP) is formed by N, L, and P 
that bind to the genomic RNA. 
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Figure 7. Replication cycle of VSV, adapted from Jianrong Li and Yu Zhang [44] VSV attachment 
is mediated by the outermost G to host cell receptors, which leads to a clathrin-mediated endocytosis. 
The ribonocleoprotein complex (RNP) is released into the cytoplasm, where transcription and 
replication takes place. Finally, the virus assembles and buds at the plasma membrane, releasing new 
virions. 
 
Vesicular stomatitis virus replicons in experimental vaccines 
At first, VSV with a deleted G gene, resulting in a propagation-incompetent VSV∆G, 
was used for pseudotyping experiments with heterologous glycoproteins [45]. Later, 
recombinant VSV vectors have been frequently used for experimental vaccination of 
mammals against a number of different pathogens such as SARS  [46], HIV-1 [47], 
human papilloma virus[48], hepatitis C virus [49], and respiratory syncytial virus [50]. 
A modified VSV vector in which the gene expressing VSV glycoprotein (G) was 
replaced by the influenza HA gene was shown to protect chicken from challenge 
infection with highly pathogenic avian influenza viruses [51, 52]. Due to the deletion 
of the G protein gene, the vector was restricted to a single round of infection 
contributing to the excellent biosafety profile of this viral vector. These single-cycle 
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virus vector vaccines were effective even though adjuvants were not employed [51, 
52]. 
 
Generation of VSV replicon particles expressing foreign antigens 
To generate replication-incompetent VSV replicon particles (VRPs) expressing high 
levels of foreign antigens, plasmids carrying the genes of interest instead of the viral 
glycoprotein G have to be designed, employing a reverse genetics system and helper 
cell lines, which are able to provide the lacking G protein in trans. (Figure 8) [53]. 
 
 
Figure 8. Generation of virus replicon particles encoding foreign antigens based on VSV, 
illustration taken from Zimmer [54]. The VSV the replicon RNA encodes for the N, P and L proteins, 
which constitute the viral RNA polymerase complex, the matrix protein M, and two heterologous 
antigens (Ag1 and Ag2). The replicon RNA lacks the gene encoding for the viral envelope glycoprotein 
G. 
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AIM OF THE PROJECT 
Outbreaks of BT disease amongst domestic and wild ruminats can cause 
considerable economic loss that reflect high morbidity and mortality as well as 
indirect losses  because of trade restrictions [10]. In the  European outbreak of BTV-8 
between 2006 and 2008, an inactivated vaccine was successfully employed. 
However, a serological discrimination between infected and vaccinated animals was 
not possible.  
In this project, we aimed on overcoming these hurdles using propagation-
incompetent VSVG vectors as a new vaccine platform against BTV, which should 
be safe, efficacious and conferred the DIVA principle.  
First, we generated VSV-virus replicon particles expressing different combinations of 
vaccine candidates and studied the expression of recombinant BTV antigens. Next, 
we assessed the immune response in a small number of sheep towards VSV VRPs 
compared to the inactivated vaccine. Immunized sheep were then infected with 
pathogenic BTV-8. Next, we immunized a small number of sheep to test the VRP’s 
general suitability, using different combinations of vaccine candidates and comparing 
results to animals immunized with the inactivated vaccine before and after infection 
with infectious BTV-8 and monitored for viremia, clinical symptoms, and antibody 
production. Taking the results from these first experiments into account, we finally 
selected propagation-incompetent VSVG vectors expressing the BTV-8 outer 
capsid proteins VP2 or VP5 , or a combination of both, and performed a blind 
vaccine/challenge study with  24 sheep. The DIVA principle was validated using a 
commercially available VP7-based competitive ELISA. 
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RESULTS 
Unpublished Results 
Generation of recombinant VSV replicons expressing BTV antigens 
The vaccine vector system is based on a vesicular stomatitis virus (VSV) deletion 
mutant that lacks the essential envelope glycoprotein G in the fourth transcription unit 
and expresses the enhanced green fluorescent protein at position 5 (VSV*∆G). By 
inserting different BTV-8 antigens of interest VP2, VP5, VP3, VP7 and the non-
structural protein NS1 and NS3 into the fourth transcription unit, we were able to 
design six different single antigen expression vectors (Figure 9). Three vectors, 
expressing two BTV-8 genes from the fourth and fifth transcription unit were also 
designed. Recombinant VSV*∆G served as a control vector as it did not express any 
BTV antigen. All recombinant vectors were propagated on helper cell lines providing 
the VSV glycoprotein G in trans, which yielded infectious virus replicon particles 
(VPRs) of approximately 108 infectious units per ml of cell culture supernatant. 
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Figure 9. Genome maps of recombinant VSV. (A) VSV encodes for nucleoprotein (N), 
phosphoprotein (P), matrix protein (M), glycoprotein (G) and the large RNA polymerase (L). In the 
VSV*∆G, the glycoprotein (G) has been replaced by the GFP gene (denoted by *). (B) The vectors 
VSV*∆G(VP2), VSV*∆G(VP5), VSV*∆G(VP3), VSV*∆G(VP7), VSV*∆G(NS1), and VSV*∆G(NS3) 
express individual antigens of BTV-8 from the fourth transcription unit while GFP (*) is expressed from 
an additional transcription unit downstream of  the BTV antigen. (C) Double expression vectors 
VSV∆G(VP2,VP5), VSV∆G(VP3,VP7), and VSV∆G(NS1, NS3) express two BTV-8 antigens from the 
fourth and fifth position. 
 
Characterization of antigen expression in vitro 
In order to study the expression of BTV antigens VP2 and VP7, we performed 
indirect immunofluorecence analysis (IFA) with Vero cells infected with VRPs using 
an MOI of 1.  
The BTV-8 VP2-specific monoclonal antibody reacted with cells infected with 
VSV*∆G(VP2) and VSV∆G(VP2, VP5), whereas cells infected with VSV*∆G were not 
recognized (Figure 10A). Expression of VP7 was detected by a VP7-specific 
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monoclonal antibody in cells infected with VSV*∆G(VP7) and VSV∆G(VP3,VP7), 
whereas cells infected with VSV*∆G were not recognized (Figure 10B). 
 
 
Figure 10. Immunofluorecence analysis of Vero cells expressing VP2 and VP7. (A) Detection of 
VP2. Cells were infected with either VSV*∆G(VP2), VSV∆G(VP2,VP5), or VSV*∆G. Expression of VP2 
is indicated by red fluorescence using a monoclonal anti-VP2 antibody (clone 13C10). Expression of 
GFP is indicated by green fluorescence. Scale bar represents 19 µm. (B) Detection of VP7. Cells were 
infected with either VSV*∆G(VP7), VSV∆G(VP3,VP7), or VSV*∆G. Expression of VP7 is indicated by 
red fluorescence using a monoclonal anti-VP7 antibody (ATCC). Expression of GFP is indicated by 
green fluorescence. Scale bar represents 19 µm. 
 
Because specific monoclonal antibody were not available, expression of VP5 and 
NS1 was confirmed using modified antigens, containing a triple FLAG epitope at the 
C-terminus. The monoclonal anti-FLAG antibody reacted specifically with Vero cells 
infected with VSV*∆G(VP5-FLAG), VSV∆G(VP2,VP5-FLAG) and VSV*∆G(NS1-
FLAG) but not with VSV*∆G(VP5)-, VSV*∆G(NS1)-, or VSV*∆G-infected cells 
(Figure 11). 
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Figure 11. Immunofluorescence analysis of Vero cells expressing VP5 and NS1. (A) Cells were 
infected with either VSV*∆G(VP5-FLAG), VSV∆G(VP2,VP5-FLAG), or VSV*∆G. Expression of VP5 is 
indicated by red fluorescence using a monoclonal anti-FLAG antibody. (B) Cells infected with either 
VSV*∆G(NS1-FLAG), or VSV*∆G. Expression of NS1 in indicated by red fluorescence using a 
monoclonal anti-FLAG antibody. 
 
For the remaining BTV antigens VP3 and NS3, monoclonal antibodies were not 
available. In order to obtain evidence for expression of these antigens, chickens were 
immunized with recombinant VSV replicons. Immune sera were then tested on Vero 
cells 24 h post infection with BTV-8 (Figure 12). All sera were found to react 
specifically with the infected cells.  
 
 
Figure 12. Immunofluorecence analysis of BTV-8 infected Vero cells stained with anti-VP3 and 
anti-NS3 immune sera. Sera obtained from chicken immunized with VSV-VRPs react with BTV-8 
infected cells (red fluorescence). Scale bar represents 24 µm. 
 
Taken together, these data show that infection of Vero cells with virus replicon 
particles (VRP) readily led to expression of BTV-8 antigens VP2, VP5, VP7 and NS1. 
 
PhD thesis Stefanie Kochinger    24 
 
Evidence of expression of BTV-8 antigens VP3 and NS3 was obtained indirectly, 
since sera of immunized chickens reacted with BTV-8 infected cells. However, 
infectious VSV was not produced by the cells due to the lack of VSV G protein 
expression. Thus, we refer to the recombinant VSV vectors as virus replicon particles 
(VRP). 
 
Analysis of antibody responses in VRP-immunized sheep 
To evaluate the immunogenicity of recombinant VRPs in a natural BTV host, nine 
seronegative sheep were immunized three times at 3-week intervals. Three animals 
were immunized with cell culture supernatant containing at least 1x108 infectious 
units of each of the VRPs VSV∆G(VP2,VP5), VSV∆G(VP3,VP7) and 
VSV∆G(NS1,NS3). Two animals were immunized with the VRPs VSV∆G(VP3,VP7) 
and VSV∆G(NS1,NS3) expressing four antigens in total. Four animals received 
VSV*∆G as control. Furthermore, five animals that  had been immunized with 
inactivated BTV-8 vaccine (BTVpur) two years ahead of the experiment were 
included in our analysis. No adverse side effects due to vaccination with VRPs were 
observed. 
Three weeks after the third immunization, sera were prepared from from sheep and  
analyzed for the presence of BTV-specific antibodies by immunofluorecence. All sera 
of sheep immunized with VRPs containing BTV antigens and BTVpur reacted 
specifically with BTV-8 infected cells, indicating that antibodies had been produced 
(Figure 13). In contrast, sera from VSV*∆G-immunized sheep did not react. 
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Figure 13. Immunofluorecence analysis of BTV-8 infected Vero cells at 24 hpi with BTV-8. Sera 
obtained from sheep after triple immunization with VSV-VRPs react with BTV-8 infected cells (red 
fluorescence). Scale bar represents 24 µm. 
 
Sera were tested for virus neutralizing activity against BTV-8. Sera of sheep before 
immunization with VSV-VRPs did not show any neutralizing activity confirming that 
the animals had no pre-existing immunity to BTV-8 (Figure 14). In contrast, sera of 
animals vaccinated with the commercially available inactivated vaccine (BTVpur) had 
neutralizing activity. Sera collected 3 weeks after the first immunization showed some 
neutralizing activity at the highest serum concentration (1:4) tested . However, 3 
weeks after the third immunization with the vaccine cocktail VSV∆G(VP2,VP5), 
VSV∆G(VP3,VP7), and VSV∆G(NS1,NS3), all animals in the group developed high 
neutralizing antibody titres against BTV-8. The same sera did not neutralize BTV-1 or 
the VSV vector (data not shown). Sheep immunized with either VSV*∆G or 
VSV∆G(VP3,VP7) in combination with VSV∆G(NS1,NS3) did not develop BTV-8 
neutralizing antibodies. Taken together, these data demonstrate that the recombinant 
VRPs induced antibodies with neutralizing activity in vitro, when VP2 and VP5 were 
expressed from the VSV vector. 
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Figure 14. Neutralizing antibodies in sera of immunized sheep. Detection of BTV-8 neutralizing 
serum antibodies. (A) Sera were prepared from VRP-immunized sheep at day 0 (first vaccination), day 
21 (second vaccination) and at day 63 (three weeks after the second immunization, prior to challenge 
infection). (B) Sera were prepared from sheep, immunized with inactivated BTV-8 vaccine (BTVpur) 
before and (14days) after infection with BTV-8. The infection or protection of cells was estimated 3 to 
5 dpi according to the development of CPE. Neutralizing titres were calculated and expressed as 
ND50/100 l. Values equal to or lower than 2 were regarded negative. 
 
VRPs expressing a combination of VP2 and VP5 antigens protect sheep from 
challenge with pathogenic BTV-8 
To evaluate the capacity of recombinant VRP vaccines to provide protection against 
pathogenic BTV-8, sheep were inoculated i.v. with erythrocyte suspension containing 
BTV-8 (Cq value of 18) 3 weeks after the second booster immunization. Sheep 
immunized with VSV*G showed characteristic signs of bluetongue disease 
beginning at 5 dpi (Figure 15A). Typical symptoms were facial edema, nasal 
discharge, and lethargy. Two animals from this group were euthanized for humane 
reasons at day 11 post infection, as they developed severe lung edema and 
respiratory distress. All animals of this groups developed high fever, which peaked at 
day 8 after infection (Figure 15B). Animals immunized with the combination of 
VSVG(VP3,VP7) and VSVG(NS1,NS3) developed milder clinical symptoms 
(Figure 15A) and recovered from moderately elevated inner body temperature 
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(Figure 15B), sooner. Animals immunized with either the combination of 
VSVG(VP2,VP5), VSVG(VP3,VP7) and VSVG(NS1,NS3) or the inactivated 
vaccine BTVpur did not develop  BTV-specific clinical signs of disease (Figure 15A) 
and had normal rectal temperature (< 39.5°C) throughout the experiment (Figure 
15B).  
 
 
Figure 15. Clinical signs of disease in BTV-8 infected sheep (A) The clinical symptoms of 
vaccinated sheep groups were monitored daily following infection with a virulent BTV-8 strain and 
scored as described in Materials and Methods. Mean values and standard deviations are indicated. 
(B) The rectal body temperature of the infected animals was determined daily for a total period of 14 
days. Body temperatures of up to 39.5°C were regarded as normal, temperatures between 39.5°C and 
40.5°C as moderately elevated, and temperatures higher than 40.5°C were defined as high fever 
(temperature limits indicated by dashed lines). Mean values and standard deviations are indicated.  
 
The capacity of the vaccine-induced immune response to suppress viremia was 
evaluated by determining viral RNA loads in blood by quantitative RT-PCR (Figure 
16). Animals immunized with either VSV*∆G or combined VSV∆G(VP3,VP7) and 
VSV∆G(NS1,NS3) had high levels of viral RNA in blood, starting from day 2 post 
challenge and lasting until the end of the experiment at day 14. In contrast, BTV RNA 
was not detected in blood of sheep immunized with either the vaccine cocktail 
VSV∆G(VP2,VP5), VSV∆G(VP3,VP7) and VSV∆G(NS1,NS3) or the inactivated 
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vaccine (BTVpur). Thus, recombinant VRPs expressing VP2 and VP5 induced 
protective immunity in sheep that prevented both viremia and bluetongue disease. 
 
 
 
Figure 16. Determination of viral RNA loads in blood of BTV-8 challenged sheep. Blood was 
collected from animals of the indicated vaccine groups every second day after infection with BTV-8. 
Total RNA was extracted from whole blood samples and RT-qPCR was performed to determine viral 
RNA loads. The quantification cycles (Cq) for detection of fluorescence signals were expressed as 50-
Cq for all 14 animals (numbered #1 to #14). 
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CONCLUSION AND OUTLOOK 
The BTV outer capsid proteins VP2 and VP5 represent potential targets for 
neutralizing antibodies. However, all neutralizing epitopes identified to date reside on 
VP2, and VP5 is thought to exert a conformational effect on VP2 (26). The present 
study demonstrates that recombinant VRPs that express the VP2 protein of BTV-8 
induce the production of serotype-specific neutralizing antibodies that protect sheep 
from disease and viremia following challenge infection with BTV-8. Our data confirm 
previous reports that have demonstrated that immunization with VP2 alone is 
sufficient to induce a protective immune response [25, 62, 63]. VP5 has been 
reported to enhance the protective immune response if present in the vaccine along 
with VP2 [27, 38]. Employing a canarypox virus vector expressing VP2 and VP5 of 
BTV-17, protection in sheep was achieved, but the relative contributions of VP2 and 
VP5 to protection have not been addressed [39]. In a recent study, expression of 
both VP2 and VP5 by a recombinant equine herpesvirus vector was necessary to 
protect mice against BTV-8 infection, whereas VP2 alone was not fully protective 
[41]. In our investigations, VRPs co-expressing VP2 and VP5 did not induce higher 
neutralizing antibody titers than VRP expressing only VP2, although one animal 
immunized with VP2 was not protected nor did it develop neutralizing antibodies. 
This discrepancy between VSV-based VRPs and other vaccines might be due to the 
different vector systems, i.e. different expression levels and differences in the 
conformation of recombinant VP2, especially if yields of recombinant VP2 are low. 
Thus, the proportion of properly folded VP2 might increase in the presence of VP5 
given their extensive conformational interaction [24]. If high expression levels of VP2 
can be achieved with a given vector system, the amounts of correctly folded VP2 
might be sufficient to induce neutralizing antibodies. Antibodies directed to VP5 may 
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not have neutralizing properties on their own, probably because this protein is not 
accessible for antibodies on the surface of the virion. Furthermore, VP5 is  more 
conserved than  VP2, suggesting  that VP5 is subject to less immune pressure. 
Conventional BTV vaccines have to be properly inactivated and formulated with 
adjuvants before they can be applied to animals once (sheep) or twice (cattle). 
Neutralizing antibodies were shown to persist up to four years after immunization [64, 
65]. The present VRP vaccine did not depend on adjuvants to induce a protective 
immune response in sheep, probably because the RNA virus vector is cytotoxic and 
so stimulates the innate immune system via pathogen recognition receptor. Any 
adverse side effects that  could be caused by adjuvants [66] are thereby eliminated. 
However, significant levels of neutralizing serum antibodies were detected only after 
the animals had been vaccinated with the VRP vaccine twice. Additional studies are 
required to determine the protective effect of a single immunization. In addition, it will 
be interesting to see for how long VRP-induced neutralizing antibodies will persist in 
sheep.  
Despite their efficacy, MLV (live-attenuated) BTV vaccines have inherent 
disadvantages, including potential transmission to vector midges, lack of attenuation, 
reassortment of gene segments with field strains of the virus, and potential to cross 
the placenta to cause reproductive losses and teratogenesis [67]. In contrast, the 
propagation-defective VRP vaccine does not cause disease nor will it be able to 
revert to virulence. As the VSV G protein which is the major immunogenic VSV 
protein is not expressed neither by the VRPs nor in non-helper cells, antibodies 
directed against the viral vector are not induced. Accordingly, VRP vaccines are 
effective when used repeatedly [51, 52, 68]. Since antibodies directed to VSV G 
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protein are lacking, vaccinated animals will appear seronegative in VSV 
neutralization tests [69]. 
Vector vaccines are superior to conventional vaccines, since they can serve as 
marker vaccines [42]. The VRP vaccine did not contain the VP7 antigen and 
therefore allowed the discrimination of infected from vaccinated animals using a 
commercially available BTV VP7 ELISA. In contrast, conventional (inactivated) BTV 
vaccines, live-attenuated and propagation-defective BTV vaccines [70, 71] do not 
comply with the DIVA principle. This has complicated the serological surveillance of 
BTV in those European countries that implemented a vaccination campaign to control 
the BTV-8 outbreak in 2006. Moreover, the inability to discriminate between infected 
and vaccinated animals had a significant impact on economy due to restrictions on 
animal trade [31]. The recombinant replicon particles eliminate this problem as they 
can be used as marker vaccines. 
There is no universal vaccine available that would protect against all 26 currently 
known serotypes of BTV. The VRP technology is not restricted to BTV-8 antigens but 
can be also used to express VP2 antigen of other BTV serotypes. Thus, in the 
scenario where  a new BTV serotype emerges in a non-endemic region, a 
recombinant VRP vaccine matching this serotype could be rapidly produced and 
used for emergency vaccination. This should be particularly valuable for BTV 
serotypes and strains for which inactivated vaccines are not readily available 
because the corresponding viruses do not propagate well in cell culture. 
Furthermore, this generic vaccine platform may be also be relevant  to protect horses 
against infection with African horse sickness virus. In summary, this study 
demonstrates that propagation-incompetent VSV replicon particles can efficiently 
protect a natural host against BT  disease and viremia. This safe and adjuvant-free 
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vaccine technology complies with the DIVA principle, can be easily adapted to other 
serotypes or other viruses, and is rapidly available in case of an emerging BTV 
outbreak. 
 
PhD thesis Stefanie Kochinger    42 
 
ACKNOWLEDGEMENTS 
 
First, I would like to express my sincere gratitude to my advisor Gert Zimmer for the 
help throughout my PhD study and research. My sincere thanks also goes to my co-
advisor Eliane Marti for encouragement, insightful comments and help. 
I want to thank external Co-advisor, Jim MacLachlan for sharing his knowledge, 
wisdom and experience with me. 
Besides my advisors, I would like to thank my excellent mentor Giuseppe Bertoni for 
continuous support, help and for being a person who I really learned to admire, both 
for his knowledge and his personal resilience. 
I thank the Institute of Virology and Immunology, Christian Griot, Kathrin 
Summermatter, Martin Hofmann, Nahalie Renevey, Barbara Thür, Andrea 
Vögtlin, Lukas Bruckner, Volker Thiel, Arthur Summerfield, Meret Ricklin, and 
all my fellow lab mates for their support and motivation throughout the past three 
years. 
I also thank my dear Austrian (Barbara Matzinger, Georg Schätz, Sonja Prucha, 
Viviane Benetka and Verena Küronya) and Swiss (Patricia Neupert, Lena Ferner, 
Claudia Wehinger, Roger Büchi, Tobias Meyer, Tobias Struchen and Daniela 
Juen) friends for all the fun, time and love you gave me. Friends like you make the 
world go round! 
Furthermore, I would like to thank my beloved family-first and foremost my gorgeous 
mother Christa, my sporty father Günther, my adventurous brother Christian, my 
caring sister Tanja and my great aunt Luise for raising me, teaching me and loving 
me the way they did and do throughout my life. I could not think of a better family! 
I also thank my boyfriend’s parents Regula and Florian Meyer for the nice family 
dinners at their place and Samuel for being both, my best friend and love. I truly 
admire, appreciate and love you just the way you are! 
 
Last but not least, I thank my Irish Setter dog Diana for being an example of patience 
and sweetness. 
 
PhD thesis Stefanie Kochinger    43 
 
CURRICULUM VITAE 
CONTACT DETAILS 
STEFANIE KOCHINGER Zollikon, Switzerland 
Fohrbachstrasse 16 • 8702 Zollikon • Switzerland 
+41 79 1247980 • stefanie.kochinger@gmx.at 
June 27, 1986 
 
PROFESSIONAL EXPERIENCE 
INSTITUTE OF VIROLOGY AND IMMUNOLOGY Mittelhäusern, Switzerland 
Development of a novel marker vaccine platform against Bluetongue  August 2011 – Juli 2014 
 Execution of BLV-granted project 
 Worked in a BSL-4 facility 
 Conducted reverse genetics, serology, animal trials, qRT-PCR, cell culture, pathology 
 Participation and presentations in national and international conferences 
 
INSTITUTE OF ANIMAL WELFARE Vienna, Austria 
Research Intern February 2011 – May 2011 
 Evaluated breeding facilities for pigs and chickens 
 
CLINICAL VIROLOGY Vienna, Austria 
Diagnostics and research assistent October 2010 – Juli 2011 
 Virological and serological testing of samples 
 Helped implementing QM-system for certification (GLP, ISO) 
 Project: Canine Parvovirus type 2; evaluation of a novel qPCR for diagnostic use 
 Teaching and supervision of students 
 
AGES INSTITUTE OF FOOD SAFETY Vienna, Austria 
Intern 
 Laboratory diagnostics milk and meat September 2011 
 
AGES PHARMMED Vienna, Austria 
Intern Registration of human therapeutics July 2009 – August 2009 
 Wrote and corrected expert opinions on human therapeutics 
 
 
PhD thesis Stefanie Kochinger    44 
 
EDUCATION 
FEDERAL FOOD SAFETY AND VETERINARY OFFICE Berne, Switzerland 
Federal veterinary officer studies 2014 
 
GRADUATE SCHOOL FOR CELLULAR AND MICROBIOLOGICAL SCIENCE Berne, Switzerland 
DVM-Ph.D. 2011-2014 
 
SVVLD - SCHWEIZER VEREINIGUNG DER VETERINÄR-LABORDIAGNOSTIKER Berne, Switzerland 
Fachtierarzt FVH für Labor- und Grundlagenmedizin, Virologie 2011-2014 
 
UNIVERSITY OF VETERINARY MEDICINE  Vienna, Austria 
Veterinary Medicine 2004-2011 
 Completed study in minimum required time with excellent success 
 Specialized in Public Health and was intern in different divisions 
 
GYMNASIUM DER DOMINIKANERINNEN Vienna, Austria 
Matura  1996 – 2004 
PERSONAL 
LANGUAGES 
 English: fluent • German: fluent (native) • French: basic  
 
TOOLS 
Microsoft Office • PrismGraph • Adobe Illustrator CS6 • Adobe Photoshop Elements 10  
 
INTERESTS 
Jogging and walking with my dog • Meeting with colleagues • Horseback riding 
Exploring new places • Skiing in winter • Reading books and papers 
LIST OF PUBLICATIONS 
Kochinger S., Renevey N., Hofmann M. A., Zimmer, G. 2014. Vesicular stomatitis virus replicon 
expressing the VP2 outer capsid protein of bluetongue virus serotype 8 induces complete 
protection of sheep against challenge infection. Vet Res  2014, 45:64. 
 
PhD thesis Stefanie Kochinger    45 
 
DECLARATION OF ORIGINALITY 
 
PhD thesis Stefanie Kochinger    46 
 
REFREFERENCES 
1. Vet Immunol ImmunopatholDNA RaHtDaT, Prof. Anica Dricu (Ed.)Erasmus, B. 
J.: Bluetongue in sheep and goats. Aust Vet J 1975, 51:165-170. 
2. van der Sluijs MT, Schroer-Joosten DP, Fid-Fourkour A, Vrijenhoek MP, 
Debyser I, Moulin V, Moormann RJ, de Smit AJ: Transplacental 
transmission of bluetongue virus serotype 1 and serotype 8 in sheep: 
virological and pathological findings. PloS one 2013, 8:e81429. 
3. Santman-Berends IM, van Wuijckhuise L, Vellema P, van Rijn PA: Vertical 
transmission of bluetongue virus serotype 8 virus in Dutch dairy herds 
in 2007. Vet Microbiol 2010, 141:31-35. 
4. Schwartz-Cornil I, Mertens PP, Contreras V, Hemati B, Pascale F, Breard E, 
Mellor PS, MacLachlan NJ, Zientara S: Bluetongue virus: virology, 
pathogenesis and immunity. Vet Res 2008, 39:46. 
5. Mellor PS, Boorman J: The transmission and geographical spread of 
African horse sickness and bluetongue viruses. Ann Trop Med Parasitol 
1995, 89:1-15. 
6. Tabachnick WJ: Culicoides variipennis and bluetongue-virus 
epidemiology in the United States. Annu Rev Entomol 1996, 41:23-43. 
7. Mellor PS, Wittmann EJ: Bluetongue virus in the Mediterranean Basin 
1998-2001. Vet J 2002, 164:20-37. 
8. Maclachlan NJ, Guthrie AJ: Re-emergence of bluetongue, African horse 
sickness, and other orbivirus diseases. Vet Res 2010, 41:35. 
9. Wilson AJ, Mellor PS: Bluetongue in Europe: past, present and future. 
Philos Trans R Soc Lond B Biol Sci 2009, 364:2669-2681. 
10. MacLachlan NJ, Osburn BI: Impact of bluetongue virus infection on the 
international movement and trade of ruminants. J Am Vet Med Assoc 
2006, 228:1346-1349. 
11. Rasmussen LD, Rasmussen TB, Belsham GJ, Strandbygaard B, Botner A: 
Bluetongue in Denmark during 2008. Vet Rec 2010, 166:714-718. 
12. Purse BV, Brown HE, Harrup L, Mertens PP, Rogers DJ: Invasion of 
bluetongue and other orbivirus infections into Europe: the role of 
biological and climatic processes. Rev Sci Tech 2008, 27:427-442. 
 
PhD thesis Stefanie Kochinger    47 
 
13. Saegerman C, Berkvens D, Mellor PS: Bluetongue epidemiology in the 
European Union. Emerg Infect Dis 2008, 14:539-544. 
14. Worwa G, Thur B, Griot C, Hofmann M, MacLachlan JN, Chaignat V: 
[Bluetongue disease in Swiss sheep breeds: clinical signs after 
experimental infection with bluetongue virus serotype 8]. Schweiz Arch 
Tierheilkd 2008, 150:491-498. 
15. Barratt-Boyes SM, MacLachlan NJ: Dynamics of viral spread in bluetongue 
virus infected calves. Vet Microbiol 1994, 40:361-371. 
16. Saegerman C, Bolkaerts B, Baricalla C, Raes M, Wiggers L, de Leeuw I, 
Vandenbussche F, Zimmer JY, Haubruge E, Cassart D, et al: The impact of 
naturally-occurring, trans-placental bluetongue virus serotype-8 
infection on reproductive performance in sheep. Vet J 2011, 187:72-80. 
17. Housawi FM, Abu Elzein EM, Ramadan RO, Gameel AA, Al-Afaleq AI, Al-
Mousa J: Abortions, stillbirths and deformities in sheep at the Al-Ahsa 
oasis in eastern Saudi Arabia: isolation of a bluetongue serogroup virus 
from the affected lambs. Rev Sci Tech 2004, 23:913-920. 
18. Wouda W, Peperkamp NH, Roumen MP, Muskens J, van Rijn A, Vellema P: 
Epizootic congenital hydranencephaly and abortion in cattle due to 
bluetongue virus serotype 8 in the Netherlands. Tijdschr Diergeneeskd 
2009, 134:422-427. 
19. Verwoerd DW, Louw H, Oellermann RA: Characterization of bluetongue 
virus ribonucleic acid. J Virol 1970, 5:1-7. 
20. Belhouchet M, Mohd Jaafar F, Firth AE, Grimes JM, Mertens PP, Attoui H: 
Detection of a fourth orbivirus non-structural protein. PloS one 2011, 
6:e25697. 
21. Mertens PP, Brown F, Sangar DV: Assignment of the genome segments of 
bluetongue virus type 1 to the proteins which they encode. Virology 1984, 
135:207-217. 
22. Mertens PP, Diprose J, Maan S, Singh KP, Attoui H, Samuel AR: Bluetongue 
virus replication, molecular and structural biology. Vet Ital 2004, 40:426-
437. 
23. Hassan SS, Roy P: Expression and functional characterization of 
bluetongue virus VP2 protein: role in cell entry. J Virol 1999, 73:9832-
9842. 
24. Zhang X, Boyce M, Bhattacharya B, Zhang X, Schein S, Roy P, Zhou ZH: 
Bluetongue virus coat protein VP2 contains sialic acid-binding domains, 
 
PhD thesis Stefanie Kochinger    48 
 
and VP5 resembles enveloped virus fusion proteins. Proc Natl Acad Sci U 
S A 2010, 107:6292-6297. 
25. Huismans H, van der Walt NT, Cloete M, Erasmus BJ: Isolation of a capsid 
protein of bluetongue virus that induces a protective immune response 
in sheep. Virology 1987, 157:172-179. 
26. DeMaula CD, Bonneau KR, MacLachlan NJ: Changes in the outer capsid 
proteins of bluetongue virus serotype ten that abrogate neutralization by 
monoclonal antibodies. Virus Res 2000, 67:59-66. 
27. Roy P, Marshall JJ, French TJ: Structure of the bluetongue virus genome 
and its encoded proteins. Curr Top Microbiol Immunol 1990, 162:43-87. 
28. Hassan SH, Wirblich C, Forzan M, Roy P: Expression and functional 
characterization of bluetongue virus VP5 protein: role in cellular 
permeabilization. J Virol 2001, 75:8356-8367. 
29. Boyer TC, Ward MP, Wallace RL, Singer RS: Regional seroprevalence of 
bluetongue virus in cattle in Illinois and western Indiana. Am J Vet Res 
2007, 68:1212-1219. 
30. Patel A, Roy P: The molecular biology of Bluetongue virus replication. 
Virus Res 2013. 
31. Savini G, MacLachlan NJ, Sanchez-Vizcaino JM, Zientara S: Vaccines 
against bluetongue in Europe. Comp Immunol Microbiol Infect Dis 2008, 
31:101-120. 
32. Veronesi E, Darpel KE, Hamblin C, Carpenter S, Takamatsu HH, Anthony SJ, 
Elliott H, Mertens PP, Mellor PS: Viraemia and clinical disease in Dorset 
Poll sheep following vaccination with live attenuated bluetongue virus 
vaccines serotypes 16 and 4. Vaccine 2010, 28:1397-1403. 
33. Batten CA, Maan S, Shaw AE, Maan NS, Mertens PP: A European field 
strain of bluetongue virus derived from two parental vaccine strains by 
genome segment reassortment. Virus Res 2008, 137:56-63. 
34. Planzer J, Kaufmann C, Worwa G, Gavier-Widen D, Hofmann MA, Chaignat 
V, Thur B: In vivo and in vitro propagation and transmission of 
Toggenburg orbivirus. Res Vet Sci 2011, 91:e163-168. 
35. Roy P, French T, Erasmus BJ: Protective efficacy of virus-like particles for 
bluetongue disease. Vaccine 1992, 10:28-32. 
36. Roy P, Bishop DH, LeBlois H, Erasmus BJ: Long-lasting protection of 
sheep against bluetongue challenge after vaccination with virus-like 
 
PhD thesis Stefanie Kochinger    49 
 
particles: evidence for homologous and partial heterologous protection. 
Vaccine 1994, 12:805-811. 
37. Hervas-Stubbs S, Rueda P, Lopez L, Leclerc C: Insect baculoviruses 
strongly potentiate adaptive immune responses by inducing type I IFN. J 
Immunol 2007, 178:2361-2369. 
38. Lobato ZI, Coupar BE, Gray CP, Lunt R, Andrew ME: Antibody responses 
and protective immunity to recombinant vaccinia virus-expressed 
bluetongue virus antigens. Vet Immunol Immunopathol 1997, 59:293-309. 
39. Boone JD, Balasuriya UB, Karaca K, Audonnet JC, Yao J, He L, Nordgren R, 
Monaco F, Savini G, Gardner IA, Maclachlan NJ: Recombinant canarypox 
virus vaccine co-expressing genes encoding the VP2 and VP5 outer 
capsid proteins of bluetongue virus induces high level protection in 
sheep. Vaccine 2007, 25:672-678. 
40. Wade-Evans AM, Romero CH, Mellor P, Takamatsu H, Anderson J, 
Thevasagayam J, Fleming MJ, Mertens PP, Black DN: Expression of the 
major core structural protein (VP7) of bluetongue virus, by a 
recombinant capripox virus, provides partial protection of sheep against 
a virulent heterotypic bluetongue virus challenge. Virology 1996, 220:227-
231. 
41. Ma G, Eschbaumer M, Said A, Hoffmann B, Beer M, Osterrieder N: An equine 
herpesvirus type 1 (EHV-1) expressing VP2 and VP5 of serotype 8 
bluetongue virus (BTV-8) induces protection in a murine infection model. 
PloS one 2012, 7:e34425. 
42. Calvo-Pinilla E, Castillo-Olivares J, Jabbar T, Ortego J, de la Poza F, Marin-
Lopez A: Recombinant vaccines against bluetongue virus. Virus Res 
2013. 
43. Hastie E, Cataldi M, Marriott I, Grdzelishvili VZ: Understanding and altering 
cell tropism of vesicular stomatitis virus. Virus Res 2013, 176:16-32. 
44. Zhang JLaY: Messenger RNA Cap Methylation in Vesicular Stomatitis 
Virus, a Prototype of Non‐Segmented Negative‐Sense RNA Virus, 
Methylation. DNA, RNA and Histones to Diseases and Treatment, Prof Anica 
Dricu (Ed) 2012. 
45. Takada A, Robison C, Goto H, Sanchez A, Murti KG, Whitt MA, Kawaoka Y: A 
system for functional analysis of Ebola virus glycoprotein. Proc Natl Acad 
Sci U S A 1997, 94:14764-14769. 
46. Kapadia SU, Simon ID, Rose JK: SARS vaccine based on a replication-
defective recombinant vesicular stomatitis virus is more potent than one 
based on a replication-competent vector. Virology 2008, 376:165-172. 
 
PhD thesis Stefanie Kochinger    50 
 
47. Publicover J, Ramsburg E, Rose JK: A single-cycle vaccine vector based 
on vesicular stomatitis virus can induce immune responses comparable 
to those generated by a replication-competent vector. J Virol 2005, 
79:13231-13238. 
48. Lichty BD, Power AT, Stojdl DF, Bell JC: Vesicular stomatitis virus: re-
inventing the bullet. Trends Mol Med 2004, 10:210-216. 
49. Majid AM, Barber GN: Recombinant Vesicular Stomatitis Virus (VSV) and 
Other Strategies in HCV Vaccine Designs and Immunotherapy. In 
Hepatitis C Viruses: Genomes and Molecular Biology. Edited by Tan SL. 
Norfolk (UK); 2006 
50. Kahn JS, Roberts A, Weibel C, Buonocore L, Rose JK: Replication-
competent or attenuated, nonpropagating vesicular stomatitis viruses 
expressing respiratory syncytial virus (RSV) antigens protect mice 
against RSV challenge. J Virol 2001, 75:11079-11087. 
51. Kalhoro NH, Veits J, Rautenschlein S, Zimmer G: A recombinant vesicular 
stomatitis virus replicon vaccine protects chickens from highly 
pathogenic avian influenza virus (H7N1). Vaccine 2009, 27:1174-1183. 
52. Halbherr SJ, Brostoff T, Tippenhauer M, Locher S, Berger Rentsch M, Zimmer 
G: Vaccination with recombinant RNA replicon particles protects 
chickens from H5N1 highly pathogenic avian influenza virus. PloS one 
2013, 8:e66059. 
53. Berger Rentsch M, Zimmer G: A vesicular stomatitis virus replicon-based 
bioassay for the rapid and sensitive determination of multi-species type I 
interferon. PloS one 2011, 6:e25858. 
54. Zimmer G: RNA Replicons - A New Approach for Influenza Virus 
Immunoprophylaxis. Viruses 2010, 2:413-434. 
55. Borden EC, Shope RE, Murphy FA: Physicochemical and morphological 
relationships of some arthropod-borne viruses to bluetongue virus--a 
new taxonomic group. Physiocochemical and serological studies. J Gen 
Virol 1971, 13:261-271. 
56. Murphy FA, Borden EC, Shope RE, Harrison A: Physicochemical and 
morphological relationships of some arthropod-borne viruses to 
bluetongue virus--a new taxonomic group. Electron microscopic studies. 
J Gen Virol 1971, 13:273-288. 
57. Hanika A, Larisch B, Steinmann E, Schwegmann-Wessels C, Herrler G, 
Zimmer G: Use of influenza C virus glycoprotein HEF for generation of 
vesicular stomatitis virus pseudotypes. J Gen Virol 2005, 86:1455-1465. 
 
PhD thesis Stefanie Kochinger    51 
 
58. Orru G, Ferrando ML, Meloni M, Liciardi M, Savini G, De Santis P: Rapid 
detection and quantitation of Bluetongue virus (BTV) using a Molecular 
Beacon fluorescent probe assay. J Virol Methods 2006, 137:34-42. 
59. Worwa G, Hilbe M, Chaignat V, Hofmann MA, Griot C, Ehrensperger F, 
Doherr MG, Thur B: Virological and pathological findings in Bluetongue 
virus serotype 8 infected sheep. Vet Microbiol 2010, 144:264-273. 
60. Worwa G, Chaignat V, Feldmann J, Thur B: Detection of neutralizing 
antibodies against Bluetongue virus serotype 8 by an optimized plasma 
neutralization test. J Virol Methods 2013, 188:168-174. 
61. Hoffmann M, Wu YJ, Gerber M, Berger-Rentsch M, Heimrich B, Schwemmle 
M, Zimmer G: Fusion-active glycoprotein G mediates the cytotoxicity of 
vesicular stomatitis virus M mutants lacking host shut-off activity. J Gen 
Virol 2010, 91:2782-2793. 
62. Top S, Foucras G, Deplanche M, Rives G, Calvalido J, Comtet L, Bertagnoli 
S, Meyer G: Myxomavirus as a vector for the immunisation of sheep: 
protection study against challenge with bluetongue virus. Vaccine 2012, 
30:1609-1616. 
63. Jabbar TK, Calvo-Pinilla E, Mateos F, Gubbins S, Bin-Tarif A, Bachanek-
Bankowska K, Alpar O, Ortego J, Takamatsu HH, Mertens PP, Castillo-
Olivares J: Protection of IFNAR (-/-) mice against bluetongue virus 
serotype 8, by heterologous (DNA/rMVA) and homologous (rMVA/rMVA) 
vaccination, expressing outer-capsid protein VP2. PloS one 2013, 
8:e60574. 
64. Oura CA, Edwards L, Batten CA: Evaluation of the humoral immune 
response in adult dairy cattle three years after vaccination with a 
bluetongue serotype 8 inactivated vaccine. Vaccine 2012, 30:112-115. 
65. Batten CA, Edwards L, Oura CA: Evaluation of the humoral immune 
responses in adult cattle and sheep, 4 and 2.5 years post-vaccination 
with a bluetongue serotype 8 inactivated vaccine. Vaccine 2013, 31:3783-
3785. 
66. Gonzalez JM, Figueras L, Ortega ME, Lozano M, de Arcaute MR, Royo R, 
Cebrian LM, Ferrer LM, Farinas F, de Jalon JA, De las Heras M: Possible 
adverse reactions in sheep after vaccination with inactivated BTV 
vaccines. Vet Rec 2010, 166:757-758. 
67. Zientara S, MacLachlan NJ, Calistri P, Sanchez-Vizcaino JM, Savini G: 
Bluetongue vaccination in Europe. Expert Rev Vaccines 2010, 9:989-991. 
68. Schwartz JA, Buonocore L, Suguitan A, Jr., Hunter M, Marx PA, Subbarao K, 
Rose JK: Vesicular stomatitis virus-based H5N1 avian influenza vaccines 
 
PhD thesis Stefanie Kochinger    52 
 
induce potent cross-clade neutralizing antibodies in rhesus macaques. J 
Virol 2011, 85:4602-4605. 
69. Roberts A, Buonocore L, Price R, Forman J, Rose JK: Attenuated vesicular 
stomatitis viruses as vaccine vectors. J Virol 1999, 73:3723-3732. 
70. Matsuo E, Celma CC, Boyce M, Viarouge C, Sailleau C, Dubois E, Breard E, 
Thiery R, Zientara S, Roy P: Generation of replication-defective virus-
based vaccines that confer full protection in sheep against virulent 
bluetongue virus challenge. J Virol 2011, 85:10213-10221. 
71. Celma CC, Boyce M, van Rijn PA, Eschbaumer M, Wernike K, Hoffmann B, 
Beer M, Haegeman A, De Clercq K, Roy P: Rapid generation of replication-
deficient monovalent and multivalent vaccines for bluetongue virus: 
protection against virulent virus challenge in cattle and sheep. J Virol 
2013, 87:9856-9864. 
 
 
